Selenium-containing histone deacetylase inhibitors for melanoma management

Cancer Biology and Therapy

Volumn 13, Issue 9, 2012, Pages 756-765

  Gowda, Raghavendra ^a,b   Madhunapantula, SubbaRao V ^a,b   Desai, Dhimant ^a   Amin, Shantu ^a   Robertson, Gavin P ^a,b  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

^b PENN STATE CANCER INSTITUTE   (United States)

Author keywords

B(PCP) 2Se; Chemoprevention; HDAC inhibitor(s); Melanoma; PCP SeCN; PI3K Akt pathway; SAHA; Selenium

Indexed keywords

5 PHENYLCARBAMOYLPENTYL SELENOCYANIDE; ANTINEOPLASTIC AGENT; BIS(5 PHENYLCARBAMOYLPENTYL)DISELENIDE; CASPASE 3; CYCLIN D1; HISTONE DEACETYLASE INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN P21; SELENIUM; UNCLASSIFIED DRUG; VORINOSTAT;

ARTICLE; CANCER INHIBITION; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFICACY; ENZYME ACTIVITY; ENZYME INHIBITION; FOOD AND DRUG ADMINISTRATION; HUMAN; HUMAN CELL; MELANOMA; PROTEIN EXPRESSION;

ANILIDES; ANTICARCINOGENIC AGENTS; APOPTOSIS; CASPASE 3; CASPASE 7; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL PROLIFERATION; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; INHIBITORY CONCENTRATION 50; MELANOMA; ORGANOSELENIUM COMPOUNDS; PHOSPHATIDYLINOSITOL 3-KINASES; SIGNAL TRANSDUCTION; SKIN NEOPLASMS; TISSUE CULTURE TECHNIQUES;

EID: 84863471450     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.20558     Document Type: Article

References (63)

1. Gray-Schopfer V, Wellbrock C, Marais R. Melanoma biology and new targeted therapy. Nature 2007; 445:851-7; PMID:17314971; http://dx.doi.org/10.1038/ nature05661.
2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics. CA Cancer J Clin 2009; 59:225-49; PMID:19474385; http://dx.doi.org/10.3322/caac. 20006.
3. Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010; 363:809-19; PMID:20818844; http://dx.doi.org/10.1056/NEJMoa1002011.
4. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363:711-23; PMID:20525992; http://dx.doi.org/10.1056/NEJMoa1003466.
5. Jemal A, Devesa SS, Hartge P, Tucker MA. Recent trends in cutaneous melanoma incidence among whites in the United States. J Natl Cancer Inst 2001; 93:678-83; PMID:11333289; http://dx.doi.org/10.1093/jnci/93.9.678.
6. Jemal A, Thomas A, Murray T, Thun M. Cancer statistics. CA Cancer J Clin 2002; 52:23-47; PMID:11814064; http://dx.doi.org/10.3322/canjclin.52.1.23.
7. Ley RD, Reeve VE. Chemoprevention of ultraviolet radiation-induced skin cancer. Environ Health Perspect 1997; 105:981-4; PMID:9255591.
8. Stratton SP, Dorr RT, Alberts DS. The state-of-theart in chemoprevention of skin cancer. Eur J Cancer 2000; 36:1292-7; PMID:10882869; http://dx.doi.org/10.1016/S0959-8049(00)00108-8.
9. Einspahr JG, Bowden GT, Alberts DS. Skin cancer chemoprevention: strategies to save our skin. Recent Results Cancer Res 2003; 163:151-64; PMID:12903851; http://dx.doi.org/10.1007/978-3-642-55647-0-14.
10. Helmbach H, Rossmann E, Kern MA, Schadendorf D. Drug-resistance in human melanoma. Int J Cancer 2001; 93:617-22; PMID:11477569; http://dx.doi.org/10. 1002/ijc.1378.
11. st century, part 1: epidemiology, risk factors, screening, prevention and diagnosis. Mayo Clin Proc 2007; 82:364-80; PMID:17352373.
12. DeLuca AM, Srinivas A, Alani RM. BRAF kinase in melanoma development and progression. Expert Rev Mol Med 2008; 10:6; PMID:18279546; http://dx.doi.org/10. 1017/S1462399408000604.
13. Madhunapantula SV, Sharma A, Robertson GP. PRAS40 deregulates apoptosis in malignant melanoma. Cancer Res 2007; 67:3626-36; PMID:17440074; http://dx.doi.org/10.1158/0008-5472.CAN-06-4234.
14. Stahl JM, Sharma A, Cheung M, Zimmerman M, Cheng JQ, Bosenberg MW, et al. Deregulated Akt3 activity promotes development of malignant melanoma. Cancer Res 2004; 64:7002-10; PMID:15466193; http://dx.doi.org/10.1158/0008-5472.CAN-04- 1399.
15. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the BRAF gene in human cancer. Nature 2002; 417:949-54; PMID:12068308; http://dx.doi.org/10.1038/nature00766.
16. Tran MA, Gowda R, Sharma A, Park EJ, Adair J, Kester M, et al. Targeting V600EB-Raf and Akt3 using nanoliposomal-small interfering RNA inhibits cutaneous melanocytic lesion development. Cancer Res 2008; 68:7638-49; PMID:18794153; http://dx.doi.org/10.1158/0008-5472.CAN-07-6614.
17. Mirmohammadsadegh A, Marini A, Nambiar S, Hassan M, Tannapfel A, Ruzicka T, et al. Epigenetic silencing of the PTEN gene in melanoma. Cancer Res 2006; 66:6546-52; PMID:16818626; http://dx.doi.org/10.1158/0008-5472.CAN-06-0384.
18. Madhunapantula SV, Robertson GP. The PTENAKT3 signaling cascade as a therapeutic target in melanoma. Pigment Cell Melanoma Res 2009; 22:400-19; PMID:19493313; http://dx.doi.org/10.1111/j.1755-148X.2009.00585.x.
19. Stahl JM, Cheung M, Sharma A, Trivedi NR, Shanmugam S, Robertson GP. Loss of PTEN promotes tumor development in malignant melanoma. Cancer Res 2003; 63:2881-90; PMID:12782594.
20. de Ruijter AJ, van Gennip AH, Caron HN, Kemp van Kuilenburg AB. Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem J 2003; 370:737-49; PMID:12429021; http://dx.doi.org/10.1042/BJ20021321.
21. Wiech NL, Fisher JF, Helquist P, Wiest O. Inhibition of histone deacetylases: a pharmacological approach to the treatment of non-cancer disorders. Curr Top Med Chem 2009; 9:257-71; PMID:19355990; http://dx.doi.org/ 10.2174/156802609788085241.
22. Marson CM. Histone deacetylase inhibitors: design, structure-activity relationships and therapeutic implications for cancer. Anticancer Agents Med Chem 2009; 9:661-92; PMID:19601748.
23. Buchwald M, Krämer OH, Heinzel T. HDACi-targets beyond chromatin. Cancer Lett 2009; 280:160-PMID:19342155; http://dx.doi.org/10.1016/j.canlet. 2009.02.028.
24. Shankar S, Srivastava RK. Histone deacetylase inhibitors: mechanisms and clinical significance in cancer: HDAC inhibitor-induced apoptosis. Adv Exp Med Biol 2008; 615:261-98; PMID:18437899; http://dx.doi.org/10.1007/978-1-4020-6554- 5-13.
25. Martínez-Iglesias O, Ruiz-Llorente L, Sánchez- Martínez R, García L, Zambrano A, Aranda A. Histone deacetylase inhibitors: mechanism of action and therapeutic use in cancer. Clin Transl Oncol 2008; 10:395-8; PMID:18628067; http://dx.doi.org/10.1007/s12094-008-0221-x.
26. Han SH. Potential role of sirtuin as a therapeutic target for neurodegenerative diseases. J Clin Neurol 2009; 5:120-5; PMID:19826562; http://dx.doi.org/10.3988/jcn.2009.5.3.120.
27. Yoshida M, Furumai R, Nishiyama M, Komatsu Nishino N, Horinouchi S. Histone deacetylase as a new target for cancer chemotherapy. Cancer Chemother Pharmacol 2001; 48:20-6; PMID:11587361; http://dx.doi.org/10.1007/s002800100300.
28. Wang C, Fu M, Mani S, Wadler S, Senderowicz AM, Pestell RG. Histone acetylation and the cell cycle in cancer. Front Biosci 2001; 6:610-29; PMID:11282573; http://dx.doi.org/10.2741/1wang1.
29. Fang JY. Histone deacetylase inhibitors, anticancerous mechanism and therapy for gastrointestinal cancers. J Gastroenterol Hepatol 2005; 20:988-94; PMID:15955204; http://dx.doi.org/10.1111/j.1440-746.2005.03807.x.
30. Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 2006; 5:769-84; PMID:16955068; http://dx.doi.org/10.1038/nrd2133.
31. Kavanaugh SM, White LA, Kolesar JM. Vorinostat: A novel therapy for the treatment of cutaneous T-cell lymphoma. Am J Health Syst Pharm 2010; 67:793-7; PMID:20479100; http://dx.doi.org/10.2146/ajhp090247.
32. Mitsiades CS, Hayden PJ, Anderson KC, Richardson PG. From the bench to the bedside: emerging new treatments in multiple myeloma. Best Pract Res Clin Haematol 2007; 20:797-816; PMID:18070720; http://dx.doi.org/10.1016/j.beha.2007. 09.008.
33. Marks PA. Discovery and development of SAHA as an anticancer agent. Oncogene 2007; 26:1351-6; PMID:17322921; http://dx.doi.org/10.1038/sj.onc. 1210204.
34. Kelly WK, Marks PA. Drug insight: Histone deacetylase inhibitors - development of the new targeted anticancer agent suberoylanilide hydroxamic acid. Nat Clin Pract Oncol 2005; 2:150-7; PMID:16264908; http://dx.doi.org/10. 1038/ncponc0106.
35. Prince HM, Bishton MJ, Harrison SJ. Clinical studies of histone deacetylase inhibitors. Clin Cancer Res 2009; 15:3958-69; PMID:19509172; http://dx.doi.org/10.1158/1078-0432.CCR-08-2785.
36. Desai D, Salli U, Vrana KE, Amin S. SelSA, selenium analogs of SAHA as potent histone deacetylase inhibitors. Bioorg Med Chem Lett 2010; 20:2044-7; PMID:20167479; http://dx.doi.org/10.1016/j.bmcl.2009.07.068.
37. Sharma A, Sharma AK, Madhunapantula SV, Desai D, Huh SJ, Mosca P, et al. Targeting Akt3 signaling in malignant melanoma using isoselenocyanates. Clin Cancer Res 2009; 15:1674-85; PMID:19208796; http://dx.doi.org/10.1158/1078-0432. CCR-08-2214.
38. Madhunapantula SV, Desai D, Sharma A, Huh SJ, Amin S, Robertson GP. PBISe, a novel selenium-containing drug for the treatment of malignant melanoma. Mol Cancer Ther 2008; 7:1297-308; PMID:18483317; http://dx.doi.org/10.1158/ 1535-7163.MCT-07-2267.
39. Soengas MS, Lowe SW. Apoptosis and melanoma chemoresistance. Oncogene 2003; 22:3138-51; PMID:12789290; http://dx.doi.org/10.1038/sj.onc.1206454.
40. Berwick M, Erdei E, Hay J. Melanoma epidemiology and public health. Dermatol Clin 2009; 27:205-14; PMID:19254665; http://dx.doi.org/10.1016/j.det. 2008.12.002.
41. Greinert R. Skin cancer: new markers for better prevention. Pathobiology 2009; 76:64-81; PMID:19367127; http://dx.doi.org/10.1159/000201675.
42. Nguyen N, Sharma A, Nguyen N, Sharma AK, Desai D, Huh SJ, et al. Melanoma chemoprevention in skin reconstructs and mouse xenografts using isoselenocyanate-4. Cancer Prev Res (Phila) 2011; 4:248-58; PMID:21097713; http://dx.doi.org/10.1158/1940-6207.CAPR-10-0106.
43. Gu W, Nusinzon I, Smith RD Jr, Horvath CM, Silverman RB. Carbonyl- and sulfur-containing analogs of suberoylanilide hydroxamic acid: Potent inhibition of histone deacetylases. Bioorg Med Chem 2006; 14:3320-9; PMID:16434199; http://dx.doi.org/10.1016/j.bmc.2005.12.047.
44. Kapustin GV, Fejér G, Gronlund JL, McCafferty DG, Seto E, Etzkorn FA. Phosphorus-based SAHA analogues as histone deacetylase inhibitors. Org Lett 2003; 5:3053-6; PMID:12916979; http://dx.doi.org/10.1021/ol035056n.
45. Mai A, Massa S, Rotili D, Cerbara I, Valente S, Pezzi R, et al. Histone deacetylation in epigenetics: an attractive target for anticancer therapy. Med Res Rev 2005; 25:261-309; PMID:15717297; http://dx.doi.org/10.1002/med.20024.
46. Chung CY, Madhunapantula SV, Desai D, Amin S, Robertson GP. Melanoma prevention using topical PBISe. Cancer Prev Res (Phila) 2011; 4:935-48; PMID:21367959; http://dx.doi.org/10.1158/1940-6207.CAPR-10-0202.
47. Dennert G, Zwahlen M, Brinkman M, Vinceti M, Zeegers MP, Horneber M. Selenium for preventing cancer. Cochrane Database Syst Rev 5195.
48. Jensen JD, Wing GJ, Dellavalle RP. Nutrition and melanoma prevention. Clin Dermatol 2010; 28:644-9; PMID:21034988; http://dx.doi.org/10.1016/j. clindermatol.2010.03.026.
49. Chen CS, Weng SC, Tseng PH, Lin HP, Chen CS. Histone acetylation- independent effect of histone deacetylase inhibitors on Akt through the reshuffling of protein phosphatase 1 complexes. J Biol Chem 2005; 280:38879-87; PMID:16186112; http://dx.doi.org/10.1074/jbc.M505733200.
50. Bali P, Pranpat M, Swaby R, Fiskus W, Yamaguchi H, Balasis M, et al. Activity of suberoylanilide hydroxamic Acid against human breast cancer cells with amplification of her-2. Clin Cancer Res 2005; 11:6382-9; PMID:16144943; http://dx.doi.org/10.1158/1078-0432.CCR-05-0344.
51. Batty N, Malouf GG, Issa JP. Histone deacetylase inhibitors as anti-neoplastic agents. Cancer Lett 2009; 280:192-200; PMID:19345475; http://dx.doi.org/10.1016/j.canlet.2009.03.013.
52. Ocker M, Schneider-Stock R. Histone deacetylase inhibitors: signalling towards p21cip1/waf1. Int J Biochem Cell Biol 2007; 39:1367-74; PMID:17412634; http://dx.doi.org/10.1016/j.biocel.2007.03.001.
53. Madhunapantula SV, Hengst J, Gowda R, Fox TE, Yun JK, Robertson GP. Targeting sphingosine kinase-1 to inhibit melanoma. Pigment Cell Melanoma Res 2012; 25:259-74; PMID:22236408; http://dx.doi.org/10.1111/j.1755-148X.2012. 00970.x.
54. Piekarz RL, Sackett DL, Bates SE. Histone deacetylase inhibitors and demethylating agents: clinical development of histone deacetylase inhibitors for cancer therapy. Cancer J 2007; 13:30-9; PMID:17464244; http://dx.doi.org/10. 1097/PPO.0b013e31803c73cc.
55. Rasheed WK, Johnstone RW, Prince HM. Histone deacetylase inhibitors in cancer therapy. Expert Opin Investig Drugs 2007; 16:659-78; PMID:17461739; http://dx.doi.org/10.1517/13543784.16.5.659.
56. Lane AA, Chabner BA. Histone deacetylase inhibitors in cancer therapy. J Clin Oncol 2009; 27:5459-68; PMID:19826124; http://dx.doi.org/10.1200/JCO.2009. 22.1291.
57. Cang S, Ma Y, Liu D. New clinical developments in histone deacetylase inhibitors for epigenetic therapy of cancer. J Hematol Oncol 2009; 2:22; PMID:19486511; http://dx.doi.org/10.1186/1756-8722-2-22.
58. Marks PA, Xu WS. Histone deacetylase inhibitors: Potential in cancer therapy. J Cell Biochem 2009; 107:600-8; PMID:19459166; http://dx.doi.org/10. 1002/jcb.22185.
59. Kato Y, Yoshimura K, Shin T, Verheul H, Hammers H, Sanni TB, et al. Synergistic in vivo antitumor effect of the histone deacetylase inhibitor MS-275 in combination with interleukin 2 in a murine model of renal cell carcinoma. Clin Cancer Res 2007; 13:4538-46; PMID:17671140; http://dx.doi.org/10.1158/1078- 0432.CCR-07-0014.
60. He R, Chen Y, Chen Y, Ougolkov AV, Zhang JS, Savoy DN, et al. Synthesis and biological evaluation of triazol-4-ylphenyl-bearing histone deacetylase inhibitors as anticancer agents. J Med Chem 2010; 53:1347-56; PMID:20055418; http://dx.doi.org/10.1021/jm901667k.
61. Quong RY, Bickford ST, Ing YL, Terman B, Herlyn M, Lassam NJ. Protein kinases in normal and transformed melanocytes. Melanoma Res 1994; 4:313-9; PMID:7858416; http://dx.doi.org/10.1097/00008390-199410000-00008.
62. Satyamoorthy K, DeJesus E, Linnenbach AJ, Kraj B, Kornreich DL, Rendle S, et al. Melanoma cell lines from different stages of progression and their biological and molecular analyses. Melanoma Res 1997; 7:35-42; PMID:9578415; http://dx.doi.org/10.1097/00008390-199708001-00007.
63. Karelia N, Desai D, Hengst JA, Amin S, Rudrabhatla SV, Yun J. Selenium-containing analogs of SAHA induce cytotoxicity in lung cancer cells. Bioorg Med Chem Lett 2010; 20:6816-9; PMID:20855208; http://dx.doi.org/10.1016/ j.bmcl.2010.08.113.